May 12, 2014 -- U.S. drugmaker Pfizer pressed the scientific case for its controversial plan to acquire AstraZeneca on Monday as its chief executive prepared for a grilling from British lawmakers on May 13 and 14.
In the latest phase of Pfizer's campaign to counter critics of its proposed $106 billion deal, research head Mikael Dolsten said he had been through five different mergers and acquisitions and denied such big transactions disrupted drug research.
"If you keep your sense of curiosity and an open mind, you can learn tremendously," he said in a video posted on the company's website.
Help employers find you! Check out all the jobs and post your resume.
